Release Date: May 30, 2025
Expiration Date: May 30, 2026
Activity Overview
With recent additions to treatment options for neovascular age-related macular degeneration (nAMD) come new questions. How can newer anti-VEGF therapies affect the treatment burden for patients with nAMD? Which patients can attain longer treatment intervals, and what are the criteria to determine the optimal interval? In this program, expert faculty presents illustrative cases of patients with nAMD managed with recently approved therapies and discusses the outcomes – including reduced treatment burden – that they can achieve.
Target Audience
Retina Specialists
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Recognize appropriate applications of evidence-based therapies used in the management of nAMD based on patient presentation and treatment goals
- Summarize the impact of advanced anti-VEGF treatments in the management of nAMD